Insider · CIK 0001677618

Vessey Rupert

Reports to the SEC for 5 companies · SOMERVILLE, MA

sec.gov

Transactions

Companies

Filings

CIK

0001677618

Forms 4 and 5

Insider transactions

50 trades

Date	Company	Role	Code	Shares	Price	Value	Shares after
2026-02-26	GENBGenerate Biomedicines, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+29.6K sh	—	—	29,561
2025-10-30	TECHBIO-TECHNE CorpA Award	Director	AAward	+1,640 sh	—	—	10,987
2025-10-30	TECHBIO-TECHNE Corp · Stock Options (Right to Buy)A Award	Director	AAward	+3,777 sh	—	—	3,777
2024-10-24	TECHBIO-TECHNE CorpA Award	Director	AAward	+1,462 sh	—	—	9,347
2024-10-24	TECHBIO-TECHNE Corp · Stock Options (Right to Buy)A Award	Director	AAward	+3,511 sh	—	—	3,511
2023-10-26	TECHBIO-TECHNE CorpA Award	Director	AAward	+1,625 sh	—	—	7,885
2023-10-26	TECHBIO-TECHNE Corp · Stock Options (Right to Buy)A Award	Director	AAward	+3,937 sh	—	—	3,937
2023-05-03	BMYBRISTOL MYERS SQUIBB COS Sale	EVP & President, Research	SSale	−50.4K sh	$67.06	−$3.38M	47,751
2023-03-10	BMYBRISTOL MYERS SQUIBB COM Exercise/Conversion	EVP & President, Research	MExercise/Conversion	+7,423 sh	—	—	68,796
2023-03-10	BMYBRISTOL MYERS SQUIBB COJ Other	EVP & President, Research	JOther	+1,373 sh	—	—	70,169
2023-03-10	BMYBRISTOL MYERS SQUIBB COF Tax Payment	EVP & President, Research	FTax Payment	−4,500 sh	$65.71	−$296K	65,669
2023-03-10	BMYBRISTOL MYERS SQUIBB COM Exercise/Conversion	EVP & President, Research	MExercise/Conversion	+7,824 sh	—	—	73,493
2023-03-10	BMYBRISTOL MYERS SQUIBB COJ Other	EVP & President, Research	JOther	+1,284 sh	—	—	74,777
2023-03-10	BMYBRISTOL MYERS SQUIBB COF Tax Payment	EVP & President, Research	FTax Payment	−4,659 sh	$65.71	−$306K	70,118
2023-03-10	BMYBRISTOL MYERS SQUIBB COM Exercise/Conversion	EVP & President, Research	MExercise/Conversion	+7,147 sh	—	—	77,265
2023-03-10	BMYBRISTOL MYERS SQUIBB COJ Other	EVP & President, Research	JOther	+231 sh	—	—	77,496
2023-03-10	BMYBRISTOL MYERS SQUIBB COF Tax Payment	EVP & President, Research	FTax Payment	−3,774 sh	$65.71	−$248K	73,722
2023-03-10	BMYBRISTOL MYERS SQUIBB COM Exercise/Conversion	EVP & President, Research	MExercise/Conversion	+44.5K sh	—	—	118,263
2023-03-10	BMYBRISTOL MYERS SQUIBB COJ Other	EVP & President, Research	JOther	+5,438 sh	—	—	123,701
2023-03-10	BMYBRISTOL MYERS SQUIBB COF Tax Payment	EVP & President, Research	FTax Payment	−25.6K sh	$65.71	−$1.68M	98,136
2023-03-10	BMYBRISTOL MYERS SQUIBB CO · Market Share UnitsM Exercise/Conversion	EVP & President, Research	MExercise/Conversion	−7,423 sh	—	—	7,425
2023-03-10	BMYBRISTOL MYERS SQUIBB CO · Market Share UnitsM Exercise/Conversion	EVP & President, Research	MExercise/Conversion	−7,824 sh	—	—	15,651
2023-03-10	BMYBRISTOL MYERS SQUIBB CO · Market Share UnitsM Exercise/Conversion	EVP & President, Research	MExercise/Conversion	−7,147 sh	—	—	21,442
2023-03-10	BMYBRISTOL MYERS SQUIBB CO · Performance SharesM Exercise/Conversion	EVP & President, Research	MExercise/Conversion	−44.5K sh	—	—	0
2022-12-02	BMYBRISTOL MYERS SQUIBB COM Exercise/Conversion	EVP & President, Research	MExercise/Conversion	+8,792 sh	—	—	65,871
2022-12-02	BMYBRISTOL MYERS SQUIBB COF Tax Payment	EVP & President, Research	FTax Payment	−4,498 sh	$81.13	−$365K	61,373
2022-12-02	BMYBRISTOL MYERS SQUIBB CO · Restricted Stock UnitsM Exercise/Conversion	EVP & President, Research	MExercise/Conversion	−8,792 sh	—	—	8,792
2022-11-07	BMYBRISTOL MYERS SQUIBB COM Exercise/Conversion	EVP & President, Research	MExercise/Conversion	+5,843 sh	$70.89	+$414K	56,228
2022-11-07	BMYBRISTOL MYERS SQUIBB COM Exercise/Conversion	EVP & President, Research	MExercise/Conversion	+21.3K sh	$72.42	+$1.54M	77,516
2022-11-07	BMYBRISTOL MYERS SQUIBB COM Exercise/Conversion	EVP & President, Research	MExercise/Conversion	+8,491 sh	$44.70	+$380K	86,007
2022-11-07	BMYBRISTOL MYERS SQUIBB COM Exercise/Conversion	EVP & President, Research	MExercise/Conversion	+8,491 sh	$47.81	+$406K	94,498
2022-11-07	BMYBRISTOL MYERS SQUIBB COM Exercise/Conversion	EVP & President, Research	MExercise/Conversion	+8,491 sh	$38.41	+$326K	102,989
2022-11-07	BMYBRISTOL MYERS SQUIBB COS Sale	EVP & President, Research	SSale	−45.9K sh	$78.88	−$3.62M	57,079
2022-11-07	BMYBRISTOL MYERS SQUIBB CO · Option (right to buy)M Exercise/Conversion	EVP & President, Research	MExercise/Conversion	−5,843 sh	—	—	0
2022-11-07	BMYBRISTOL MYERS SQUIBB CO · Option (right to buy)M Exercise/Conversion	EVP & President, Research	MExercise/Conversion	−21.3K sh	—	—	0
2022-11-07	BMYBRISTOL MYERS SQUIBB CO · Option (right to buy)M Exercise/Conversion	EVP & President, Research	MExercise/Conversion	−8,491 sh	—	—	0
2022-11-07	BMYBRISTOL MYERS SQUIBB CO · Option (right to buy)M Exercise/Conversion	EVP & President, Research	MExercise/Conversion	−8,491 sh	—	—	0
2022-11-07	BMYBRISTOL MYERS SQUIBB CO · Option (right to buy)M Exercise/Conversion	EVP & President, Research	MExercise/Conversion	−8,491 sh	—	—	0
2022-10-27	TECHBIO-TECHNE CorpA Award	Director	AAward	+338 sh	—	—	1,565
2022-10-27	TECHBIO-TECHNE Corp · Stock Options (Right to Buy)A Award	Director	AAward	+865 sh	—	—	865
2022-03-16	BMYBRISTOL MYERS SQUIBB COS Sale	EVP & President, Research	SSale	−31.3K sh	$69.27	−$2.17M	46,308
2022-03-16	BMYBRISTOL MYERS SQUIBB COM Exercise/Conversion	EVP & President, Research	MExercise/Conversion	+21.3K sh	$66.35	+$1.41M	67,596
2022-03-16	BMYBRISTOL MYERS SQUIBB COM Exercise/Conversion	EVP & President, Research	MExercise/Conversion	+5,294 sh	$55.52	+$294K	72,890
2022-03-16	BMYBRISTOL MYERS SQUIBB COM Exercise/Conversion	EVP & President, Research	MExercise/Conversion	+12.2K sh	$54.29	+$664K	85,123
2022-03-16	BMYBRISTOL MYERS SQUIBB COM Exercise/Conversion	EVP & President, Research	MExercise/Conversion	+8,490 sh	$38.41	+$326K	93,613
2022-03-16	BMYBRISTOL MYERS SQUIBB COS Sale	EVP & President, Research	SSale	−43.2K sh	$69.23	−$2.99M	50,385
2022-03-16	BMYBRISTOL MYERS SQUIBB CO · Option (right to buy)M Exercise/Conversion	EVP & President, Research	MExercise/Conversion	−21.3K sh	—	—	0
2022-03-16	BMYBRISTOL MYERS SQUIBB CO · Option (right to buy)M Exercise/Conversion	EVP & President, Research	MExercise/Conversion	−12.2K sh	—	—	0
2022-03-16	BMYBRISTOL MYERS SQUIBB CO · Option (right to buy)M Exercise/Conversion	EVP & President, Research	MExercise/Conversion	−5,294 sh	—	—	0
2022-03-16	BMYBRISTOL MYERS SQUIBB CO · Option (right to buy)M Exercise/Conversion	EVP & President, Research	MExercise/Conversion	−8,490 sh	—	—	8,491

Recent filings

Accepted (ET)
Mar 24
Vessey Rupert0001193125-26-085952
SEC(opens sec.gov)
Nov 34
Vessey Rupert0000914190-25-000017
SEC(opens sec.gov)
Apr 114/A
VESSEY RUPERT0001062993-25-007369
SEC(opens sec.gov)
Oct 284
VESSEY RUPERT0001062993-24-018033
SEC(opens sec.gov)
Oct 304
VESSEY RUPERT0001062993-23-019854
SEC(opens sec.gov)
May 44
VESSEY RUPERT0000014272-23-000114
SEC(opens sec.gov)
Mar 144
VESSEY RUPERT0000014272-23-000068
SEC(opens sec.gov)

Companies

Address

GENERATE BIOMEDICINES, INC. 101 SOUTH STREET, SUITE 900

SOMERVILLE, MA, 02143